Last reviewed 2026-04-20 · How we verify

GB-5001A

G2GBio, Inc. · Phase 1 active Small molecule Quality 0/100

GB-5001A is a Small molecule drug developed by G2GBio, Inc.. It is currently in Phase 1 development.

GB-5001A is an investigational formulation of donepezil being developed by G2GBio, Inc. for intramuscular and subcutaneous administration. It is currently in Phase 1 clinical trials, assessing safety, tolerability, and pharmacokinetics compared to oral donepezil. The drug aims to improve patient compliance and therapeutic outcomes in conditions like Alzheimer's disease.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GB-5001A
Sponsor	G2GBio, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GB-5001A CI brief — competitive landscape report
GB-5001A updates RSS · CI watch RSS
G2GBio, Inc. portfolio CI

Frequently asked questions about GB-5001A

What is GB-5001A?

GB-5001A is a Small molecule drug developed by G2GBio, Inc..

Who makes GB-5001A?

GB-5001A is developed by G2GBio, Inc. (see full G2GBio, Inc. pipeline at /company/g2gbio-inc).

What development phase is GB-5001A in?

GB-5001A is in Phase 1.

Manufacturer: G2GBio, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing